MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bph.70058

Медицинская библиотека · British journal of pharmacology · 2025

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.

Toumi Eya, Bestion Eloïne, Militello Muriel, Lepidi Hubert, Plauzolles Anne, Bardin Nathalie, Bertin Daniel, Chiche Laurent, Mege Jean-Louis, Halfon Philippe, Mezouar Soraya

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Systemic lupus erythematosus is an autoimmune, multisystemic disease affecting all organs in the body. Accrued evidence has elucidated a role for autophagy in the onset and severity of systemic lupus erythematosus. The antimalarial drug hydroxychloroquine constitutes the cornerstone of standard of care for systemic lupus erythematosus, together with glucocorticoids and immunosuppressants or biologics, and all accompanied by various side effects.

EXPERIMENTAL APPROACH AND

OBJECTIVE

Our study aimed to investigate the potential of GNS561 (ezurpimtrostat) treatment, a small basic lipophilic molecule that induces lysosomal dysregulation, using the pristane-induced lupus mouse model.

KEY

RESULTS

Compared with hydroxychloroquine, GNS561 treatment presents a more pronounced impact on the development of pathogenic anti-antibodies in pristane-induced lupus mice. Next, focussing on clinical impact, we showed that GNS561 significantly reduced clinical signs of lupus in pristane-induced lupus by preventing the incidence and severity of arthritis, occurrence of nephritis and lung damage. Finally, GNS561 modulated the inflammatory profile in pristane-induced lupus mice through a reduction of the lipogranuloma score. Interestingly, focussing on interferon-α, only pristane-induced lupus mice treated by GNS561 presented a significant decrease of the cytokine, suggesting a higher efficacy for GNS561 in the modulation of lupus-induced inflammation compared with hydroxychloroquine.

CONCLUSION

All results show that GNS561, but not hydroxychloroquine, represents as an effective treatment to prevent clinical and inflammatory signs of lupus in this mouse model.

IMPLICATIONS: Altogether, this study highlights GNS561 as a promising investigational drug for systemic lupus erythematosus.

Для цитирования: Toumi Eya, Bestion Eloïne, Militello Muriel, Lepidi Hubert, Plauzolles Anne, Bardin Nathalie, Bertin Daniel, Chiche Laurent, Mege Jean-Louis, Halfon Philippe, Mezouar Soraya. GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.. British journal of pharmacology. 2025. DOI: 10.1111/bph.70058.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.